Results of an ongoing phase 1/2a dose escalation study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager, in patients with metastatic castration-resistant prostate cancer (mCRPC).

Johann S. de Bono,Lawrence Fong,Tomasz M. Beer,Xin Gao,Daniel M. Geynisman,Howard A. Burris,James Strauss,Kevin D. Courtney,David I. Quinn,David J. VanderWeele,Yifah Yaron,Che Leung Law,Mark N. Stein

Results of an ongoing phase 1/2a dose escalation study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager, in patients with metastatic castration-resistant prostate cancer (mCRPC).

2021

Johann S. de Bono
Lawrence Fong
Tomasz M. Beer
Xin Gao
Daniel M. Geynisman
Howard A. Burris
James Strauss
Kevin D. Courtney
David I. Quinn
David J. VanderWeele
Yifah Yaron
Che Leung Law
Mark N. Stein

5013Background: HPN424 is a prostate-specific membrane antigen (PSMA)-targeting T cell engager designed to redirect T cells to kill PSMA-expressing prostate cancer cells; engineered with three bind...

Keywords:

in patient
membrane antigen
Cancer research
Medicine
dose escalation
Half-life
T cell
Prostate cancer
castration resistant

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations